BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOTBiotechnology
-$0.03 today
- Market cap
- $149.27M
- Beta
- 0.29
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$4.95
Volume 0.37M
Average 0.37M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOT
Intrinsic Alpha fair value
Locked
Current Price
$1.86
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | N/A | N/A6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Kodiak Sciences Inc. NASDAQ:KOD | $6.99B | $111.19 | Not rated | -9.6 | +401.28% |
Tango Therapeutics, Inc. NASDAQ:TNGX | $4.32B | $25.50 | Not rated | -38.9 | +173.94% |
Xencor, Inc. NASDAQ:XNCR | $2.78B | $37.09 | Not rated | -5.5 | +115.66% |
Septerna, Inc. NASDAQ:SEPN | $2.03B | $42.60 | Undervalued | -43.6 | +69.70% |
Nurix Therapeutics, Inc. NASDAQ:NRIX | $1.69B | $15.48 | Undervalued | -6.4 | -5.09% |
AnaptysBio, Inc. NASDAQ:ANAB | $1.38B | $46.25 | Overvalued | -59.7 | +92.14% |
UroGen Pharma Ltd. NASDAQ:URGN | $1.28B | $26.18 | Not rated | -12.2 | +25.56% |
Phathom Pharmaceuticals, Inc. NASDAQ:PHAT | $492.63M | $6.06 | Not rated | -5.6 | -65.65% |
Oculis Holding AG NASDAQ:OCS | $471.63M | $7.64 | Not rated | -5.5 | -61.39% |
Continue the stock analysis
Jump to another research area for this company.